Previous 10 | Next 10 |
Please click here to access all 3Q2021 results related documents The Hague, November 11, 2021 - C onsistent execut ion on strategic initiatives ; results impacted by adverse mortality experience Net loss of EUR 60 million reflects a EUR 470 m...
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 4, 2021 – The $11-trillion healthcare industry is going fully digital, disrupting industry giants & government monopolies, and finally giving the power back to the people....
The Hague, November 2, 2021 - Aegon announces today that it has committed to transition its EUR 156 billion general account investment portfolio to net-zero greenhouse gas emissions by 2050. This is an important step in the strengthening of Aegon’s group-wide approach towards corpora...
Attorneys say CoolSculpting risks include irreversible damage to patients, especially men Consumer-rights and personal injury law firm Hagens Berman has launched a nationwide investigation into CoolSculpting regarding the risk of permanent disfigurement and serious harm ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene editing could revolutionize the way we treat diseases. By removing cells from the body, modifying them and reintroducing them, therapies could treat cancers, cystic fibrosis, sickle cell and muscular dystrophy. At so...
Aegon N.V. (Amsterdam:AGN) (NYSE:AEG): Improved operating performance; dividend well covered by Free Cash Flows Net loss of EUR 147 million in the second half of 2020, mainly as a result of an increase of the value of liabilities in the Netherlands due to tightening credit spr...
I sold out of Tiffany but will make the case for a hold or even a buy. The deal isn't very attractive in the light of other special-situations and M&A events that are going on. However, the risk-adjusted return looks extremely attractive. For further details see: Tif...
Option calculations help guide us to an accurate assessment of our covered-call-writing profits. It’s more meaningful to use percentages rather than dollar amounts when executing these calculations, explains Alan Ellman of The Blue Collar Investor. For further details see: Rollin...
New York's Department of Financial Services filed civil charges against Johnson & Johnson (NYSE: JNJ) on Thursday, accusing the biopharmaceutical gian t of downplaying the risks to patients associated with the use of prescription opioids. Specifically, the state accuses Johnson & ...
As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has built an attractive portfolio of d...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...
2024-03-27 17:08:02 ET A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related cos...
2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...